RxDoctor Payments Data

Makenzie Utterback, PA

Medical · Terre Haute, INNPI 1649888744

Payments from drug & device makers

$1,937in general payments, 2019–2025

Across 66 payments — averaging $29.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$409
  • Novartis$258
  • E.r. Squibb & Sons, L.L.C.$256
  • Amgen$239
  • Johnson & Johnson$236
  • Boston Scientific$206
  • plus $333 from 8 others

What the payments were for

  • Food & beverage$1,937100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,937 in reported general payments places this provider in the 75th percentile of 273 medical providers in Indiana.

See all medical providers in Indiana

Medicare billing

Part B allowed, 2024
$84,216
Medicare patients
704
Services billed
1,299

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban68$58,490
EntrestoSacubitril/Valsartan29$25,644
JardianceEmpagliflozin24$24,857
Repatha SureclickEvolocumab19$10,431
XareltoRivaroxaban11$8,112
Ranolazine ErRanolazine37$3,402
Isosorbide Mononitrate ErIsosorbide Mononitrate219$1,915
Losartan Potassium187$1,382
Amlodipine Besylate180$961
Metoprolol Succinate86$914
Hydralazine Hcl73$784
Carvedilol90$759
ClopidogrelClopidogrel Bisulfate64$718
Atorvastatin Calcium147$635
Metoprolol Tartrate167$591

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$52$58,49068 claims
NovartisEntresto$258$25,64429 claims
Boehringer IngelheimJardiance$409$24,85724 claims
Johnson & JohnsonXarelto$236$8,11211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 273 medical providers in Indiana.

Other medical in Terre Haute

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →